Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy Taniguchi M; Tsurikisawa N; Higashi N; Saito H; Mita H; Mori A; Sakakibara H; Akiyama KAllergol Int 2007[Jun]; 56 (2): 97-103Churg-Strauss syndrome (CSS) is characterized by the presence of asthma, eosinophilia, and small-vessel vasculitis with granuloma. It is a distinct entity, as determined from all classifications of systemic vasculitis. The poor prognostic factors in CSS are renal insufficiency, cardiomyopathy, severe gastrointestinal (GI) tract, and central nervous systems (CNS) involvement. The initial management of CSS should include a high dose of a corticosteroid: prednisone at 1 mg/kg/day or its equivalent for methylprednisolone with tapering over 6 months. In patients with severe or rapidly progressing CSS, the administration of methylprednisolone pulse at 1 g/body/day for 3 days is recommended. When corticosteroid therapy does not induce remission, or when patients have poor prognostic factors, immunosuppressive cytotoxic therapy is indicated. However, some patients with severe CSS often show resistance to conventional treatment. We think that IVIG therapy is a hopeful candidate for second-line treatment for CSS patients, particularly in the case of neuropathy and/or cardiomyopathy, which are resistant to conventional therapy. However, there is not much evidence supporting the effectiveness of IVIG in CSS, and the mechanisms underlying the action of IVIG remain unclear. Now we are performing clinical trials of IVIG therapy for CSS patients who are resistant to conventional treatment, through a nationwide double-blinded placebo-controlled study in Japan.|*Salvage Therapy[MESH]|Adrenal Cortex Hormones/therapeutic use[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Biomarkers/urine[MESH]|Churg-Strauss Syndrome/*drug therapy/immunology/urine[MESH]|Cyclophosphamide/therapeutic use[MESH]|Humans[MESH]|Immunoglobulins, Intravenous/*therapeutic use[MESH]|Immunologic Factors/*therapeutic use[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Interferon-alpha/therapeutic use[MESH]|Leukotriene E4/urine[MESH]|Methylprednisolone/therapeutic use[MESH]|Plasma Exchange[MESH]|Prednisolone/therapeutic use[MESH]|Remission Induction[MESH]|Treatment Failure[MESH]|Treatment Outcome[MESH] |